Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 5/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360596 | 1.00 | HTT (0.41) | HTTCYP1A2ACECYP2C19NR1I2 | |
| SCHEMBL14012825 | 0.95 | SMN1; SMN2 (0.43) | HTTCYP1A2CYP2C19NR1I2LMNA | |
| SCHEMBL884218 | 0.89 | HTT (0.50) | HTTCYP1A2ACECYP2C19REN | |
| SCHEMBL29625486 | 0.89 | ACE (0.43) | HTTACEOPRD1 | |
| SCHEMBL2162311 | 0.89 | HTT (0.50) | HTTCYP1A2ACECYP2C19REN | |
| SCHEMBL28093144 | 0.87 | HTT (0.42) | HTTNR1I2OPRD1LMNA | |
| SCHEMBL1360593 | 0.85 | CYP1A2 (0.40) | CYP1A2ACECYP2C19NR1I2REN | |
| SCHEMBL1466679 | 0.84 | HTT (0.40) | HTTNR1I2OPRD1LMNA | |
| SCHEMBL7974526 | 0.84 | ACE (0.44) | CYP1A2ACECYP2C19RENLMNA | |
| SCHEMBL16106745 | 0.84 | HTT (0.40) | HTTNR1I2OPRD1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| CN-1315028-C | Position Chinese character inputting method | LI JIANXUE (CN) | 2007-05-09 | — | — | CN | disclosed |
| CN-1235617-C | Containing magnesium ascorbyl phosphate and UNINONTAN-U34TMSkin whitening composition (preparation containing cucumber extract and lemon extract) | MARY KAY INC (US) | 2006-01-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | HTT 3335/4885CYP1A2 1529/4885ACE 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.